We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biogen delivered strong financial results in the first quarter driven by the solid operational performance of our [multiple sclerosis], [spinal muscular atrophy] and biosimilars franchises ...